Literature DB >> 29276274

Formulary Drug Review: Naldemedine.

Danial E Baker1.   

Abstract

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are available online to subscribers. Monographs can be customized to meet the needs of a facility. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, contact Wolters Kluwer customer service at 866-397-3433. The September 2017 monograph topics are brigatinib, durvalumab, edaravone, midostaurin, and sarilumab. The MUE is on sarilumab.

Entities:  

Year:  2017        PMID： 29276274      PMCID： PMC5735716          DOI： 10.1177/0018578717724805

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN： 0018-5787


  9 in total

1.  Oral methylnaltrexone for opioid-induced constipation.

Authors:  C S Yuan; J F Foss
Journal:  JAMA       Date:  2000-09-20       Impact factor: 56.272

2.  Extended-release but not immediate-release and subcutaneous methylnaltrexone antagonizes the loperamide-induced delay of whole-gut transit time in healthy subjects.

Authors:  Julia Kolbow; Christiane Modess; Danilo Wegner; Stefan Oswald; Martina Alice Maritz; Hélène Rey; Werner Weitschies; Werner Siegmund
Journal:  J Clin Pharmacol       Date:  2015-10-20       Impact factor: 3.126

Review 3.  Opioid-induced constipation: advances and clinical guidance.

Authors:  Alfred D Nelson; Michael Camilleri
Journal:  Ther Adv Chronic Dis       Date:  2016-01-25       Impact factor: 5.091

4.  Increased Burden of Healthcare Utilization and Cost Associated with Opioid-Related Constipation Among Patients with Noncancer Pain.

Authors:  Ancilla W Fernandes; David M Kern; Catherine Datto; Yen-Wen Chen; Charles McLeskey; Ozgur Tunceli
Journal:  Am Health Drug Benefits       Date:  2016-05

Review 5.  Opioid-induced constipation: challenges and therapeutic opportunities.

Authors:  Michael Camilleri
Journal:  Am J Gastroenterol       Date:  2011-02-22       Impact factor: 10.864

6.  The safety and efficacy of oral methylnaltrexone in preventing morphine-induced delay in oral-cecal transit time.

Authors:  C S Yuan; J F Foss; J Osinski; A Toledano; M F Roizen; J Moss
Journal:  Clin Pharmacol Ther       Date:  1997-04       Impact factor: 6.875

7.  Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain.

Authors:  Roger Chou; Gilbert J Fanciullo; Perry G Fine; Jeremy A Adler; Jane C Ballantyne; Pamela Davies; Marilee I Donovan; David A Fishbain; Kathy M Foley; Jeffrey Fudin; Aaron M Gilson; Alexander Kelter; Alexander Mauskop; Patrick G O'Connor; Steven D Passik; Gavril W Pasternak; Russell K Portenoy; Ben A Rich; Richard G Roberts; Knox H Todd; Christine Miaskowski
Journal:  J Pain       Date:  2009-02       Impact factor: 5.820

Review 8.  Novel Oral Therapies for Opioid-induced Bowel Dysfunction in Patients with Chronic Noncancer Pain.

Authors:  Renee M Holder; Diane Rhee
Journal:  Pharmacotherapy       Date:  2016-03-06       Impact factor: 4.705

9.  Naloxegol for opioid-induced constipation in patients with noncancer pain.

Authors:  William D Chey; Lynn Webster; Mark Sostek; Jaakko Lappalainen; Peter N Barker; Jan Tack
Journal:  N Engl J Med       Date:  2014-06-04       Impact factor: 91.245
  9 in total
  1 in total

Review 1.  Insights into the Use of Peripherally Acting μ-Opioid Receptor Antagonists (PAMORAs) in Oncologic Patients: from Scientific Evidence to Real Clinical Practice.

Authors:  Ana Fernández-Montes; Guillermo de Velasco; Santiago Aguín; Cristina Farriols; María Guirado-Risueño; Vanessa G Jerviz-Guía; María Victoria Baeza-Nadal; Rodolfo Chicas-Sett; José Luis Fírvida; Francisco García-Navalón; Patricia Martín; Carmen Perezagua-Marín; Dulce Rodríguez; Joan Santamaría; Tamara Saurí; Manuel Cobo
Journal:  Curr Treat Options Oncol       Date:  2021-02-26
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.